cloudy.png
Thursday January 20th, 2022 3:08PM

Biogen cuts the price tag on its Alzheimer's drug in half

By The Associated Press
Related Articles
  Contact Editor

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually.

The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50% next month. That means the annual cost for a person of average weight will amount to $28,200.

The actual amount that person would pay will depend on factors like insurance coverage.

Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to “financial considerations,” and their disease had progressed beyond the point where Aduhelm could help.

Aduhelm is the first in a line of new drugs that promise to do what no other Alzheimer’s treatment has managed: slow the progress of the fatal brain-destroying disease, rather than just managing its symptoms.

The drug received FDA approval in June, and the agency later said it was appropriate for patients with mild symptoms or early-stage Alzheimer’s.

But Aduhelm's debut has been slowed by concerns over the price. Some insurers have balked at paying for the drug, while medical centers across the country have been either slow to decide on using the drug or said they weren't planning to prescribe it for now.

Doctors have said concerns over the price were compounded by costs patients also would face for regular testing and scans needed to monitor their progress on Aduhelm.

The initial price also has been cited as a key factor behind planned premium hikes for Medicare, the federal government’s coverage program for people ages 65 and older and for the disabled.

Last month, Medicare announced one of the largest increases ever in its “Part B” monthly premium for outpatient care. It said it would raise the premium nearly $22, from $148.50 currently to $170.10 starting in January.

The agency said about half of that hike was due to the need for a contingency fund to cover Aduhelm. Medicare is expected to be one main payers for the drug.

Biogen said in October that Aduhelm had brought in only $300,000 in sales during its first full quarter on the market. The company attributed that figure partly to drug wholesalers drawing down inventory they had purchased the previous quarter.

Aduhelm clears brain plaque thought to play a role in Alzheimer’s disease, and regulators made their call based on study results showing the drug seemed likely to benefit patients. But they’ve asked for more research.

Biogen, which developed Aduhelm with Japan’s Eisai Co., said last week the company expects to screen the first patients for that study in May. It will aim to enroll about 1,300 people with early-stage Alzheimer’s and expects to complete the research about four years after the study begins.

Biogen also said Monday that it will start some cost-cutting measures that are expected to yield about $500 million in annual savings, most of which will be realized next year. The company said it was cutting costs in part because the slow debut of Aduhem was affecting its revenue.

Shares of Biogen Inc., based in Cambridge, Massachusetts, slipped in early trading along with broader markets.

  • Associated Categories: Associated Press (AP), AP Health, AP Business, AP Business - Corporate News, AP Health - Senior Health
© Copyright 2022 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Biogen cuts the price tag on its Alzheimer's drug in half
Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually
9:50AM ( 4 minutes ago )
US stocks fall in early trading. continuing a weak stretch
Stocks are falling in early trading Monday, continuing a weak stretch as traders keep a wary eye on global increases in COVID-19 cases
9:44AM ( 9 minutes ago )
Red snow? A most unexpected modern standard for the holidays
When he sat down at his parents' house to write a simple, melodic song for his band Fleet Foxes' debut album, Robin Pecknold had no idea he'd be writing a modern-day holiday standard
9:35AM ( 18 minutes ago )
Associated Press (AP)
Jurors start weighing evidence in Elizabeth Holmes' case
The jurors now responsible for assessing 11 charges of fraud and conspiracy against former Theranos CEO Elizabeth Holmes are scheduled to begin their first full day of deliberations on Monday
8:46AM ( 1 hour ago )
Jurors starts weighing evidence in Elizabeth Holmes' case
The jurors now responsible for assessing 11 charges of fraud and conspiracy against former Theranos CEO Elizabeth Holmes are scheduled to begin their first full day of deliberations on Monday
8:44AM ( 1 hour ago )
Moderna: Initial booster data shows good results on omicron
Moderna said Monday that a booster dose of its COVID-19 vaccine should offer protection against the rapidly spreading omicron variant
8:03AM ( 1 hour ago )
AP Health
Leftist millennial vows to remake Chile after historic win
Former student leader Gabriel Boric will be under quick pressure from his youthful supporters to fulfill his promises to remake Chile after the millennial politician won the country’s presidential runoff
8:11AM ( 1 hour ago )
Pandemic again forces delay in plans for next Davos meeting
The World Economic Forum is again delaying its much-ballyhooed annual meeting of world leaders, business executives and other elites in Davos, Switzerland, amid new uncertainties about the omicron variant of the coronavirus
8:10AM ( 1 hour ago )
Holiday season lights a bright spot amid pandemic resurgence
The holiday season is shining brightly despite COVID-19
7:58AM ( 1 hour ago )
AP Business
Medicare urged to flex its power and slash back premium hike
The head of a Senate panel that oversees Medicare says the Biden administration should cut back a hefty premium increase soon to hit millions of enrollees
2:33PM ( 6 days ago )
German lawmakers back vaccine mandate for health workers
German lawmakers have overwhelmingly backed a bill that requires staff at hospitals and nursing homes to get vaccinated against the coronavirus
7:54AM ( 1 week ago )
German lawmakers debate 1st, partial vaccine mandate
German lawmakers are debating a bill Friday that would require staff at hospitals and nursing homes to get vaccinated against the coronavirus or risk losing their jobs
5:38AM ( 1 week ago )
AP Health - Senior Health
US stocks fall in early trading. continuing a weak stretch
Stocks are falling in early trading Monday, continuing a weak stretch as traders keep a wary eye on global increases in COVID-19 cases
9:44AM ( 10 minutes ago )
Red snow? A most unexpected modern standard for the holidays
When he sat down at his parents' house to write a simple, melodic song for his band Fleet Foxes' debut album, Robin Pecknold had no idea he'd be writing a modern-day holiday standard
9:35AM ( 19 minutes ago )
EU approves 5th COVID-19 vaccine for bloc, one by Novavax
The European Union’s drugs regulator has given the green light to a fifth COVID-19 vaccine for use in the 27-nation bloc, granting conditional marketing authorization to the two-dose vaccine made by U.S. biotech company Novavax
9:21AM ( 32 minutes ago )
Manchin upends Biden's agenda, won't back $2 trillion bill
Sen. Joe Manchin has all but delivered a death blow to President Joe Biden’s $2 trillion domestic initiative
9:09AM ( 45 minutes ago )
Pro-Beijing candidates sweep Hong Kong elections
Pro-Beijing candidates have won a landslide victory in Hong Kong’s legislative elections, beating out moderates and independents in the city’s first polls since Beijing passed a resolution to amend the city’s election laws to ensure that only “patriots” loyal to Beijing could run the city
9:08AM ( 46 minutes ago )